{"id":111197,"date":"2026-06-10T10:53:23","date_gmt":"2026-06-10T08:53:23","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/"},"modified":"2026-06-10T14:48:49","modified_gmt":"2026-06-10T12:48:49","slug":"connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/","title":{"rendered":"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome"},"content":{"rendered":"

CONNECTA Therapeutics<\/a>, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, located at the Barcelona Science Park, today announced the initiation of its Phase IIa clinical trial evaluating its lead first-in-class program, CTH120, in adult males with fragile X syndrome (FXS).<\/strong><\/p>\n

CTH120 is a novel small\u2011molecule targeting the tropomyosin receptor kinase B (TrkB), a key regulator of neuroplasticity, the brain\u2019s ability to form and adapt neural connections. Impaired neuroplasticity is a core pathophysiological feature in neurodevelopmental disorders and contributes to the clinical manifestations observed in conditions such as FXS. FXS is the most common inherited cause of intellectual disability, with an estimated prevalence of approximately 3 per 10,000 individuals.<\/p>\n

\u201cInitiating this Phase IIa study represents a significant milestone for CONNECTA,\u201d said Jordi F\u00e0brega<\/strong>, Co\u2011Founder and CEO of CONNECTA Therapeutics. \u201cBuilding on encouraging Phase I safety data, this trial is designed to further evaluate the safety and tolerability of CTH120 and to generate critical insights into its potential therapeutic benefit by modulating pathways implicated in disrupted neuronal function in FXS. We believe this study could support the development of a novel, disease\u2011modifying approach for FXS and serve as an important proof point for our broader neuroplasticity modulation platform.\u201d<\/p>\n

The Phase IIa randomized, double\u2011blind, placebo\u2011controlled, parallel\u2011group, multicenter study (EU CT number: 2025\u2011522972\u201197\u201100) is designed to evaluate CTH120 administered twice daily versus placebo. The first clinical trial will be conducted in individuals most severely affected by FXS, who are typically adult males due to the X-linked nature of the condition. The primary endpoint is the assessment of safety and tolerability, with secondary endpoints including characterization of pharmacokinetics and evaluation of clinical efficacy. The trial will randomize 30 adult males aged 18\u201345, in 1:1 ratio to receive CTH120 or placebo. Successful completion of the study will represent an important step toward later\u2011stage clinical development of CTH120.<\/p>\n

\u201cFXS has a profound impact on cognitive and behavioral function, severely affecting the quality of life of individuals living with the condition and their families. It remains a condition with significant unmet medical need, with no approved disease\u2011modifying treatments,\u201d said Dr. Rafael de la Torre Fornell<\/strong>, PharmD, PhD, Principal Investigator and Study Coordinator at Hospital del Mar Research Institute (HMRIB). \u201cThis Phase IIa trial provides an important opportunity to evaluate a promising new mechanism of action and advance clinical understanding of this lifelong condition.\u201d<\/p>\n

The Phase IIa study will be conducted at Hospital del Mar Research Institute (HMRIB) in Barcelona and Parc Taul\u00ed Research and Innovation Institute Foundation (I3PT) in Sabadell, two leading centers with broad expertise in FXS and neurodevelopmental disorders. The study is led by Dr. Rafael de la Torre Fornell<\/strong>, PharmD, PhD, as well as Ana Aldea Perona<\/strong>, MD, PhD (HMRIB) and Ana Roche Mart\u00ednez<\/strong>, MD, PhD (I3PT). Under the leadership of Mara Dierssen<\/strong>, PhD, at the Centre for Genomic Regulation (CRG), the clinical trial will also contribute to advancing the identification of disease-specific biomarkers underlying the neurobiology of FXS and to assessing treatment response.<\/p>\n

The study has been authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS), with approvals from the relevant ethics committees, and is funded by the Spanish Ministry of Science, Innovation and Universities and the European Union\u2019s NextGeneration EU program (Project reference: CPP2022\u2011009659).<\/p>\n

\u00bb Link to the news: <\/strong>CONNECTA Therapeutics website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, located at the Barcelona Science Park, today announced the…<\/p>\n","protected":false},"author":14,"featured_media":111191,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[90],"tags":[277],"class_list":["post-111197","post","type-post","status-publish","format-standard","has-post-thumbnail","category-entities","tag-connecta-therapeutics-en"],"acf":[],"yoast_head":"\nCONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"CTH120 is a novel small\u2011molecule targeting the tropomyosin receptor kinase B (TrkB), a key regulator of neuroplasticity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"CTH120 is a novel small\u2011molecule targeting the tropomyosin receptor kinase B (TrkB), a key regulator of neuroplasticity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T08:53:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T12:48:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/06\/CONNECTATherapeutics-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome\",\"datePublished\":\"2026-06-10T08:53:23+00:00\",\"dateModified\":\"2026-06-10T12:48:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/\"},\"wordCount\":576,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/CONNECTATherapeutics-1.jpg\",\"keywords\":[\"CONNECTA Therapeutics\"],\"articleSection\":[\"ENTITIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/\",\"name\":\"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/CONNECTATherapeutics-1.jpg\",\"datePublished\":\"2026-06-10T08:53:23+00:00\",\"dateModified\":\"2026-06-10T12:48:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"CTH120 is a novel small\u2011molecule targeting the tropomyosin receptor kinase B (TrkB), a key regulator of neuroplasticity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/CONNECTATherapeutics-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/CONNECTATherapeutics-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome - Parc Cient\u00edfic de Barcelona","description":"CTH120 is a novel small\u2011molecule targeting the tropomyosin receptor kinase B (TrkB), a key regulator of neuroplasticity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome - Parc Cient\u00edfic de Barcelona","og_description":"CTH120 is a novel small\u2011molecule targeting the tropomyosin receptor kinase B (TrkB), a key regulator of neuroplasticity.","og_url":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-06-10T08:53:23+00:00","article_modified_time":"2026-06-10T12:48:49+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/06\/CONNECTATherapeutics-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome","datePublished":"2026-06-10T08:53:23+00:00","dateModified":"2026-06-10T12:48:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/"},"wordCount":576,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/06\/CONNECTATherapeutics-1.jpg","keywords":["CONNECTA Therapeutics"],"articleSection":["ENTITIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/","url":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/","name":"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/06\/CONNECTATherapeutics-1.jpg","datePublished":"2026-06-10T08:53:23+00:00","dateModified":"2026-06-10T12:48:49+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"CTH120 is a novel small\u2011molecule targeting the tropomyosin receptor kinase B (TrkB), a key regulator of neuroplasticity.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/06\/CONNECTATherapeutics-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/06\/CONNECTATherapeutics-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/111197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=111197"}],"version-history":[{"count":3,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/111197\/revisions"}],"predecessor-version":[{"id":111221,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/111197\/revisions\/111221"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/111191"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=111197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=111197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=111197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}